Latest Conference Coverage

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.

The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.

The neurologist from Massachusetts General Hospital gave an overview of her study presented at ACTRIMS.

Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.

Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.

The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.

The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.

Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.

Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.

The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.

The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.

The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.

The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.

Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.

The director of the Dartmouth Epilepsy Program and chairwoman of AES 2020 discussed some of the major topics from the previously completed annual meeting and where epilepsy research is trending.

Despite significant improvements in Dravet syndrome, non-statistically significant reductions were observed in children with Lennox-Gastaut Syndrome.

The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.

Data suggest that treatment-emergent adverse events with adjunctive brivaracetam increased in incidence by number of lifetime AEDs.

The neurologist from Cleveland Clinic discussed perampanel’s unique mechanism of action.

The director of the Dartmouth Epilepsy Program discussed a few of the notable highlights and themes from the recently completed American Epilepsy Society Annual Meeting.

The observed increase in QOLIE-31 scores for patients with refractory disease was driven by increases on the energy-fatigue domain.

Valproic acid’s efficacy as a monotherapy is complicated by its previously demonstrated unsuitability for pregnant women.

Specific health-related quality of life measures in physical activities, well-being, cognition, and social activities were improved among those who underwent the laser ablation procedure.

The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.

William Rosenfeld, MD, discusses the decreases his team observed in concomitant medication use with cenobamate in patients with focal seizures.